All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


The Impact of Acute Major Bleeding: Patient Outcomes, Costs, and Practical Considerations

A Breakfast Symposium to be Conducted at the 2019 ASHP Summer Meeting & Exhibition

Tuesday, June 11, 2019, 6:15 AM - 7:45 AM ET
Sheraton Boston (Headquarter Hotel) - Grand Ballroom, 2nd floor


Register to attend in Boston 

Register to attend via Webinar

Activity Description

With over 33.5 million people worldwide with atrial fibrillation and an estimated 900,000 people in the United States affected by venous thromboembolism (VTE), direct oral anticoagulation (DOAC) use is on the rise. Use of any anticoagulant medication, however, increases the risk of bleeding and may further complicate patient outcomes. Of particular concern are major bleeds occurring in critical sites such as in the case of intracranial hemorrhage (ICH). This activity will evaluate the clinical impact of acute major bleeding and examine safety and efficacy data surrounding the use of oral anticoagulant reversal agents. Faculty will discuss administration streamlining and dosing efficiency techniques, and an interactive question and answer session will provide learners an opportunity to address lingering questions.

Learning Objectives

The target audience for this activity includes clinical and health-system pharmacists, emergency medicine pharmacists, pharmacy directors, chief pharmacy officers, and managed care pharmacists. At the completion of this symposium, the participant will be able to:

  • Describe the clinical impact of acute major bleeding for patients on oral anticoagulant therapies.
  • Compare and contrast FDA-approved oral anticoagulant reversal agents.
  • Discuss up-to-date safety and efficacy data surrounding the use of oral anticoagulation reversal.
  • Examine strategies to streamline administration of oral anticoagulant reversal agents and dosing efficiency techniques.


5:45 AM Registration and Breakfast
6:15 AM – 7:45 AM CE Activity
Pre-registration is encouraged, and will be used for planning purposes. Seating will be available on a first-come, first-served basis. On-site registration will be available, space permitting.


Christian T. Ruff, MD, MPH
Director of General Cardiology
Brigham and Women’s Hospital
Harvard Medical School
TIMI Study Group
Boston, Massachusetts

Jessica M. Rimsans, PharmD, BCPS
Clinical Pharmacy Specialist
Hemostatic and Antithrombotic Stewardship
Brigham and Women’s Hospital
Department of Pharmacy Services
Boston, Massachusetts

CE Accreditation


ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-163-L01-P has been assigned to this live knowledge-based activity (initial release date 6-11-2019). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation no later than July 12, 2019 to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Rimsans has no relevant commercial or financial relationships to disclose. Dr. Ruff has received Research Support from Boehringer Ingelheim, Daiichi Sankyo, MedImmune, and the National Institutes of Health, and is an Advisory Board member and/or Consultant for Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, MedImmune, Pfizer, and Portola. A portion of grant funds received by ProCE from Portola Pharmaceuticals, Inc. will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider or Portola Pharmaceuticals, Inc. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is provided by ProCE, Inc. and is supported by an educational grant from Portola Pharmaceuticals, Inc.


Register to attend in Boston 

Register to attend via Webinar 

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.